Skip to Main Content
Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 2022, Issue 1
December 9 2022
Issue Cover

Table of Contents

Ham-Wasserman Lecture

Leukemogenesis in infants and young children with trisomy 21
Irene Roberts
View Articletitled, Leukemogenesis in infants and young children with trisomy 21

Acute Myeloid Leukemia: Improving Outcomes in Challenging Subsets

Achieving MRD negativity in AML: how important is this and how do we get there?
Christopher S. Hourigan
View Articletitled, Achieving MRD negativity in AML: how important is this and how do we get there?
Novel investigational approaches for high-risk genetic subsets of AML: TP53, KMT2A, FLT3
Kieran D. Sahasrabudhe,Alice S. Mims
View Articletitled, Novel investigational approaches for high-risk genetic subsets of AML: <em>TP53</em>, <em>KMT2A</em>, <em>FLT3</em>
Optimizing outcomes in secondary AML
Andrew Matthews,Keith W. Pratz
View Articletitled, Optimizing outcomes in secondary AML
Evidence-Based Minireview: Clinical utilization of panel-based molecular testing for patients with AML
Brandon J. Aubrey,Andrew Brunner
View Articletitled, Evidence-Based Minireview: Clinical utilization of panel-based molecular testing for patients with AML

Anxiety Provoking Consultations: Mast Cells and Eosinophils

Available and emerging therapies for bona fide advanced systemic mastocytosis and primary eosinophilic neoplasms
Jason Gotlib
View Articletitled, Available and emerging therapies for bona fide advanced systemic mastocytosis and primary eosinophilic neoplasms
Approach to the patient with suspected hypereosinophilic syndrome
Amy D. Klion
View Articletitled, Approach to the patient with suspected hypereosinophilic syndrome
How to evaluate the patient with a suspected mast cell disorder and how/when to manage symptoms
Cem Akin
View Articletitled, How to evaluate the patient with a suspected mast cell disorder and how/when to manage symptoms

Are Alternative Donors Now Mainstream in Allogeneic Transplant?

In 2022, which is preferred: haploidentical or cord transplant?
Arnon Nagler,Mohamad Mohty
View Articletitled, In 2022, which is preferred: haploidentical or cord transplant?
Supplemental data
New strategies for mismatched unrelated donor (MMUD) hematopoietic cell transplant (HCT)
Shukaib Arslan,Monzr M. Al Malki
View Articletitled, New strategies for mismatched unrelated donor (MMUD) hematopoietic cell transplant (HCT)
Hematology 2022—what is complete HLA match in 2022?
Stephen R. Spellman
View Articletitled, Hematology 2022—what is complete HLA match in 2022?

Autoimmune Hemolytic Anemias

Cold AIHA and the best treatment strategies
Jenny McDade Despotovic,Taylor Olmsted Kim
View Articletitled, Cold AIHA and the best treatment strategies
Evaluating patients with autoimmune hemolytic anemia in the transfusion service and immunohematology reference laboratory: pretransfusion testing challenges and best transfusion-management strategies
Susan T. Johnson,Kathleen E. Puca
View Articletitled, Evaluating patients with autoimmune hemolytic anemia in the transfusion service and immunohematology reference laboratory: pretransfusion testing challenges and best transfusion-management strategies
Warm autoimmune hemolytic anemia and the best treatment strategies
David J. Kuter
View Articletitled, Warm autoimmune hemolytic anemia and the best treatment strategies

Beyond Routine Frontline Therapy of CML

Transplantation in CML in the TKI era: who, when, and how?
Christian Niederwieser,Nicolaus Kröger
View Articletitled, Transplantation in CML in the TKI era: who, when, and how?
Treatment of CML in pregnancy
Harry F. Robertson,Jane F. Apperley
View Articletitled, Treatment of CML in pregnancy
Management of TKI-resistant chronic phase CML
Timothy P. Hughes,Naranie Shanmuganathan
View Articletitled, Management of TKI-resistant chronic phase CML

Controversies in Aggressive NHL

CNS prophylaxis in aggressive B-cell lymphoma
Matthew R. Wilson,Sabela Bobillo,Kate Cwynarski
View Articletitled, CNS prophylaxis in aggressive B-cell lymphoma
Sequencing therapy in relapsed DLBCL
Christopher R. Flowers,Oreofe O. Odejide
View Articletitled, Sequencing therapy in relapsed DLBCL
What is the role of up-front autologous stem cell transplantation in mantle cell lymphoma?
Anita Kumar
View Articletitled, What is the role of up-front autologous stem cell transplantation in mantle cell lymphoma?

Immunotherapy in Multiple Myeloma

Antibodies and bispecifics for multiple myeloma: effective effector therapy
Christopher Cipkar,Christine Chen,Suzanne Trudel
View Articletitled, Antibodies and bispecifics for multiple myeloma: effective effector therapy
Beyond the cell: novel noncellular immunotherapy approaches to multiple myeloma
Sarah A. Holstein
View Articletitled, Beyond the cell: novel noncellular immunotherapy approaches to multiple myeloma
Cellular therapy for multiple myeloma: what's now and what's next
Paula Rodriguez-Otero,Jesús F. San-Miguel
View Articletitled, Cellular therapy for multiple myeloma: what's now and what's next

Improving Outcomes in ALL

New developments in ALL in AYA
Nicolas Boissel
View Articletitled, New developments in ALL in AYA
Optimal approach to T-cell ALL
Kristen M. O'Dwyer
View Articletitled, Optimal approach to T-cell ALL
Ph+ ALL in 2022: is there an optimal approach?
Matthew J. Wieduwilt
View Articletitled, Ph+ ALL in 2022: is there an optimal approach?
Evidence-Based Minireview: What is the optimal tyrosine kinase inhibitor for adults with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia?
Fadi G. Haddad,Nicholas J. Short
View Articletitled, Evidence-Based Minireview: What is the optimal tyrosine kinase inhibitor for adults with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia?

JAK/STAT Inhibition and Beyond in Ph-Negative MPNs

Hitting the brakes on accelerated and blast-phase myeloproliferative neoplasms: current and emerging concepts
Jan Philipp Bewersdorf,Raajit K. Rampal
View Articletitled, Hitting the brakes on accelerated and blast-phase myeloproliferative neoplasms: current and emerging concepts
Molecular prognostication in Ph-negative MPNs in 2022
Alessandro Maria Vannucchi,Paola Guglielmelli
View Articletitled, Molecular prognostication in Ph-negative MPNs in 2022
New approaches to tackle cytopenic myelofibrosis
Samuel B. Reynolds,Kristen Pettit
View Articletitled, New approaches to tackle cytopenic myelofibrosis

Long-Term Effects Monitoring for Survivors of Pediatric Hematologic Malignancies

Germline risk factors for second malignant neoplasms after treatment for pediatric hematologic malignancies
Smita Bhatia
View Articletitled, Germline risk factors for second malignant neoplasms after treatment for pediatric hematologic malignancies
Mitigating, monitoring, and managing long-term chemotherapy- and radiation-induced cardiac toxicity
Wendy Bottinor,Eric J. Chow
View Articletitled, Mitigating, monitoring, and managing long-term chemotherapy- and radiation-induced cardiac toxicity
Risk factors and screening for neurocognitive impacts of therapy
Kevin R. Krull
View Articletitled, Risk factors and screening for neurocognitive impacts of therapy

Long-Term Health Effects of Curative Therapy for Sickle Cell Disease

Knowledge to date on secondary malignancy following hematopoietic cell transplantation for sickle cell disease
Courtney D. Fitzhugh
View Articletitled, Knowledge to date on secondary malignancy following hematopoietic cell transplantation for sickle cell disease
Long-term health outcomes following curative therapies for sickle cell disease
Rohini Chakravarthy,Debra L. Friedman
View Articletitled, Long-term health outcomes following curative therapies for sickle cell disease
Organ function indications and potential improvements following curative therapy for sickle cell disease
Monica L. Hulbert,Allison A. King,Shalini Shenoy
View Articletitled, Organ function indications and potential improvements following curative therapy for sickle cell disease
Evidence-Based Minireview: How to utilize new therapies for sickle cell disease
Stephanie Guarino,Sophie Lanzkron
View Articletitled, Evidence-Based Minireview: How to utilize new therapies for sickle cell disease

Managing Thrombocytopenia in Challenging Situations

Thrombopoietin receptor agonists for chemotherapy-induced thrombocytopenia: a new solution for an old problem
Hanny Al-Samkari
View Articletitled, Thrombopoietin receptor agonists for chemotherapy-induced thrombocytopenia: a new solution for an old problem
Thrombocytopenia and liver disease: pathophysiology and periprocedural management
Hana I. Lim,Adam Cuker
View Articletitled, Thrombocytopenia and liver disease: pathophysiology and periprocedural management
Thrombocytopenia in pregnancy
Allyson M. Pishko,Ariela L. Marshall
View Articletitled, Thrombocytopenia in pregnancy
Evidence-Based Minireview: Full dose, modified dose, or no anticoagulation for patients with cancer and acute VTE and thrombocytopenia
Rushad Patell,Jeffrey I. Zwicker
View Articletitled, Evidence-Based Minireview: Full dose, modified dose, or no anticoagulation for patients with cancer and acute VTE and thrombocytopenia

Maximizing Outcomes in CLL

Novel therapies and combinations in CLL refractory to BTK inhibitors and venetoclax
Lydia Scarfò
View Articletitled, Novel therapies and combinations in CLL refractory to BTK inhibitors and venetoclax
Selecting initial therapy in CLL
Inhye E. Ahn,Jennifer R. Brown
View Articletitled, Selecting initial therapy in CLL
Treatment of Richter's syndrome
Philip A. Thompson,Tanya Siddiqi
View Articletitled, Treatment of Richter's syndrome

Multiple Myeloma: Assessing the Patient and the Disease

Fitness and frailty in myeloma
Charlotte Pawlyn,Abdullah M. Khan,Ciara L. Freeman
View Articletitled, Fitness and frailty in myeloma
High or low? Assessing disease risk in multiple myeloma
Timothy Martin Schmidt
View Articletitled, High or low? Assessing disease risk in multiple myeloma
The burden of myeloma: novel approaches to disease assessment
Matthew Ho,Taxiarchis Kourelis
View Articletitled, The burden of myeloma: novel approaches to disease assessment
Mitigating the risk of venous thromboembolism in patients with multiple myeloma receiving immunomodulatory-based therapy
Fahrettin Covut,Kristen M. Sanfilippo
View Articletitled, Mitigating the risk of venous thromboembolism in patients with multiple myeloma receiving immunomodulatory-based therapy

Novel Approaches in MDS

New investigational combinations for higher-risk MDS
Kristin L. Koenig,Uma Borate
View Articletitled, New investigational combinations for higher-risk MDS
Risk stratifying MDS in the time of precision medicine
Mario Cazzola
View Articletitled, Risk stratifying MDS in the time of precision medicine
Targeting inflammation in lower-risk MDS
Jesus D. Gonzalez-Lugo,Amit Verma
View Articletitled, Targeting inflammation in lower-risk MDS<sup></sup>

Obstetric Management and Complications in Sickle Cell Disease in High- and Low-Income Countries

Acute pain episodes, acute chest syndrome, and pulmonary thromboembolism in pregnancy
Eugenia Vicky Asare,Michael R. DeBaun,Edeghonghon Olayemi,Theodore Boafor,Samuel A. Oppong
View Articletitled, Acute pain episodes, acute chest syndrome, and pulmonary thromboembolism in pregnancy
Evidence-based management of pregnant women with sickle cell disease in high-income countries
Eugene Oteng-Ntim,Panicos Shangaris
View Articletitled, Evidence-based management of pregnant women with sickle cell disease in high-income countries
Evidence-based obstetric management of women with sickle cell disease in low-income countries
Bosede B. Afolabi,Ochuwa A. Babah,Titilope A. Adeyemo
View Articletitled, Evidence-based obstetric management of women with sickle cell disease in low-income countries

Prophylactic Platelet Transfusions

Novel platelet products including cold-stored platelets
Dana V. Devine
View Articletitled, Novel platelet products including cold-stored platelets
Expanding the platelet inventory to mitigate the impact of severe shortages
James R. Stubbs,Beth H. Shaz,Ralph R. Vassallo,John D. Roback
View Articletitled, Expanding the platelet inventory to mitigate the impact of severe shortages
Platelet components and bacterial contamination: hospital perspective 2022
Zbigniew M. Szczepiorkowski,Monica B. Pagano
View Articletitled, Platelet components and bacterial contamination: hospital perspective 2022
Evidence-Based Minireview: Strategies to manage a severely HLA-alloimmunized patient with refractory thrombocytopenia
Debbie Jiang,Sandhya R. Panch
View Articletitled, Evidence-Based Minireview: Strategies to manage a severely HLA-alloimmunized patient with refractory thrombocytopenia

Reproductive and Sexual Health in Sickle Cell Disease

Incorporating gonadal health counseling into pediatric care of sickle cell patients
Lillian R. Meacham,Lydia H. Pecker,Beatrice Gee,Adrienne Mishkin
View Articletitled, Incorporating gonadal health counseling into pediatric care of sickle cell patients
Epidemiology and treatment of priapism in sickle cell disease
Ibrahim M. Idris,Arthur L. Burnett,Michael R. DeBaun
View Articletitled, Epidemiology and treatment of priapism in sickle cell disease
No crystal stair: supporting fertility care and the pursuit of pregnancy in women with sickle cell disease
Lydia H. Pecker,Alecia Nero,Mindy Christianson
View Articletitled, No crystal stair: supporting fertility care and the pursuit of pregnancy in women with sickle cell disease

Thrombosis and Anticoagulation: Clinical Considerations in Selected Populations

Anticoagulant therapy for women: implications for menstruation, pregnancy, and lactation
Emma DeLoughery,Bethany Samuelson Bannow
View Articletitled, Anticoagulant therapy for women: implications for menstruation, pregnancy, and lactation
Thrombosis and anticoagulation: clinical issues of special importance to hematologists who practice in Asia
Kochawan Boonyawat,Pantep Angchaisuksiri
View Articletitled, Thrombosis and anticoagulation: clinical issues of special importance to hematologists who practice in Asia
Thrombosis questions from the inpatient wards
George Goshua,Pavan K. Bendapudi,Alfred Ian Lee
View Articletitled, Thrombosis questions from the inpatient wards
Evidence-Based Minireview: Should caplacizumab be used routinely in unselected patients with immune thrombotic thrombocytopenic purpura?
George Goshua,Pavan K. Bendapudi
View Articletitled, Evidence-Based Minireview: Should caplacizumab be used routinely in unselected patients with immune thrombotic thrombocytopenic purpura?

Thrombosis Prevention and Treatment

Coming soon to a pharmacy near you? FXI and FXII inhibitors to prevent or treat thromboembolism
Omri Cohen,Walter Ageno
View Articletitled, Coming soon to a pharmacy near you? FXI and FXII inhibitors to prevent or treat thromboembolism
To prophylax or not, and how much and how long? Controversies in VTE prevention for medical inpatients, including COVID-19 inpatients
Alex C. Spyropoulos
View Articletitled, To prophylax or not, and how much and how long? Controversies in VTE prevention for medical inpatients, including COVID-19 inpatients
The 5 most frequently asked questions about factor Xa inhibitors
Tzu-Fei Wang,Marc Carrier
View Articletitled, The 5 most frequently asked questions about factor Xa inhibitors

To Transplant or Not to Transplant in Active or High-Risk Myeloid Disease

Transplant for TP53-mutated MDS and AML: because we can or because we should?
Jurjen Versluis,R. Coleman Lindsley
View Articletitled, Transplant for TP53-mutated MDS and AML: because we can or because we should?
Transplant in AML with measurable residual disease: proceed or defer?
Charles Craddock
View Articletitled, Transplant in AML with measurable residual disease: proceed or defer?
Allogeneic transplantation for advanced acute leukemia
Daniel Weisdorf
View Articletitled, Allogeneic transplantation for advanced acute leukemia

Treatment Approaches for the Multiple Myeloma Patient in 2022

Newly diagnosed multiple myeloma: making sense of the menu
Caitlin L. Costello
View Articletitled, Newly diagnosed multiple myeloma: making sense of the menu
The consultant's guide to smoldering multiple myeloma
Sigrun Thorsteinsdottir,Sigurdur Yngvi Kristinsson
View Articletitled, The consultant's guide to smoldering multiple myeloma
The first relapse in multiple myeloma: how to pick the next best thing
Srinivas Devarakonda,Nidhi Sharma,Yvonne Efebera
View Articletitled, The first relapse in multiple myeloma: how to pick the next best thing

Update in Hemophilia

Gene therapy for hemophilia
Amit C. Nathwani
View Articletitled, Gene therapy for hemophilia
Long-term prophylaxis: what are our options and how to define success?
Marilyn Jean Manco-Johnson,Beth Boulden Warren
View Articletitled, Long-term prophylaxis: what are our options and how to define success?
Perioperative hemostasis for patients with hemophilia
Jacqueline N Poston,Rebecca Kruse-Jarres
View Articletitled, Perioperative hemostasis for patients with hemophilia

Updates in Targeted Therapy in Pediatric Leukemia

Clinical screening for Ph-like ALL and the developing role of TKIs
Thai Hoa Tran,Sarah K. Tasian
View Articletitled, Clinical screening for Ph-like ALL and the developing role of TKIs
The evolution of targeted therapy in pediatric AML: gemtuzumab ozogamicin, FLT3/IDH/BCL2 inhibitors, and other therapies
Lauren Pommert,Katherine Tarlock
View Articletitled, The evolution of targeted therapy in pediatric AML: gemtuzumab ozogamicin, FLT3/IDH/BCL2 inhibitors, and other therapies
Updates in infant acute lymphoblastic leukemia and the potential for targeted therapy
Rishi S. Kotecha
View Articletitled, Updates in infant acute lymphoblastic leukemia and the potential for targeted therapy

Von Willebrand Disease

Diagnostic pitfalls and conundrums in type 1 von Willebrand disease
Robert F. Sidonio,Michelle Lavin
View Articletitled, Diagnostic pitfalls and conundrums in type 1 von Willebrand disease
Special considerations in GI bleeding in VWD patients
Nicholas L.J. Chornenki,Edwin Ocran,Paula D. James
View Articletitled, Special considerations in GI bleeding in VWD patients
What have we learned about the patient's experience of von Willebrand disease? A focus on women
Heather VanderMeulen,Sumedha Arya,Sarah Nersesian,Natalie Philbert,Michelle Sholzberg
View Articletitled, What have we learned about the patient's experience of von Willebrand disease? A focus on women

What is New in Classical Bone Marrow Failure Syndromes? (Focus on Management)

Dyskeratosis congenita and telomere biology disorders
Sharon A. Savage
View Articletitled, Dyskeratosis congenita and telomere biology disorders
Modern management of Fanconi anemia
Carlo Dufour,Filomena Pierri
View Articletitled, Modern management of Fanconi anemia
Genetics of severe congenital neutropenia as a gateway to personalized therapy
Jean Donadieu,Christine Bellanné-Chantelot
View Articletitled, Genetics of severe congenital neutropenia as a gateway to personalized therapy

What's New in Indolent Lymphoma

Divergent paths: management of early relapsed follicular lymphoma
Radhika Takiar,Yasmin Karimi,Tycel J. Phillips
View Articletitled, Divergent paths: management of early relapsed follicular lymphoma
Management of marginal zone lymphomas
Michele Merli,Luca Arcaini
View Articletitled, Management of marginal zone lymphomas
Biology of follicular lymphoma: insights and windows of clinical opportunity
Megan Perrett,Carina Edmondson,Jessica Okosun
View Articletitled, Biology of follicular lymphoma: insights and windows of clinical opportunity
Evidence-Based Minireview: When should autologous transplant or cellular therapy be considered for follicular lymphoma?
David A. Bond,Ajay K. Gopal
View Articletitled, Evidence-Based Minireview: When should autologous transplant or cellular therapy be considered for follicular lymphoma?

Where Are We Headed in Hodgkin Lymphoma?

Do all patients with primary refractory/first relapse of HL need autologous stem cell transplant?
Alison J. Moskowitz
View Articletitled, Do all patients with primary refractory/first relapse of HL need autologous stem cell transplant?
Incorporating novel agents into frontline treatment of Hodgkin lymphoma
Swetha Kambhampati,Alex F. Herrera
View Articletitled, Incorporating novel agents into frontline treatment of Hodgkin lymphoma
Individualized patient care in nodular lymphocyte-predominant Hodgkin lymphoma
Sven Borchmann
View Articletitled, Individualized patient care in nodular lymphocyte-predominant Hodgkin lymphoma

Errata

Burnett AE, Ragheb B, Kaatz S. Perioperative consultative hematology: can you clear my patient for a procedure? Hematology Am Soc Hematol Educ Program. 2021;2021:521-528.
AE Burnett,B Ragheb,S Kaatz
View Articletitled, Burnett AE, Ragheb B, Kaatz S. Perioperative consultative hematology: can you clear my patient for a procedure? <em>Hematology Am Soc Hematol Educ Program</em>. 2021;2021:521-528.
Williams KM. Noninfectious complications of hematopoietic cell transplantation. Hematology Am Soc Hematol Educ Program. 2021;2021:578-586.
KM Williams
View Articletitled, Williams KM. Noninfectious complications of hematopoietic cell transplantation. <em>Hematology Am Soc Hematol Educ Program</em>. 2021;2021:578-586.
Thilagar B, Beidoun M, Rhoades R, Kaatz S. COVID-19 and thrombosis: searching for evidence. Hematology Am Soc Hematol Educ Program. 2021;2021:621-627.
B Thilagar,M Beidoun,R Rhoades,S Kaatz
View Articletitled, Thilagar B, Beidoun M, Rhoades R, Kaatz S. COVID-19 and thrombosis: searching for evidence. <em>Hematology Am Soc Hematol Educ Program</em>. 2021;2021:621-627.
All Issues
Medical consult: aHUS, TTP? How to distinguish and what to do
Management of limited-stage Hodgkin lymphoma
Consumptive coagulopathy in the ICU
Pyruvate kinase activators for treatment of pyruvate kinase deficiency
Preventing relapse after CD19 CAR T-cell therapy for pediatric ALL: the role of transplant and enhanced CAR T cells
  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal